Karine Malagu

AZD8055 Is a Potent, Selective, and Orally Bioavailable ATP-Competitive Mammalian Target of Rapamycin Kinase Inhibitor with <i>In vitro</i> and <i>In vivo</i> Antitumor Activity

Christine M. Chresta, Barry R. Davies, Ian Hickson et al. · Cancer Research · 2009 · 790 citations · Full text

Mtorc2 Substrate Akt, Cell Death, Pharmacotherapy +21

Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: The discovery of AZD8055 and AZD2014

Kurt G. Pike, Karine Malagu, Marc Hummersone et al. · Bioorganic & Medicinal Chemistry Letters · 2013 · 204 citations · Full text

Molecular Docking, Medicinal Chemistry, Drug Target +12

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

Karine Malagu, Heather M. E. Duggan, Keith Menear et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 79 citations · Full text

Combinatorial Chemistry, Medicinal Chemistry, Drug Target +11

Identification and optimisation of novel and selective small molecular weight kinase inhibitors of mTOR

Keith Menear, Sylvie Gomez, Karine Malagu et al. · Bioorganic & Medicinal Chemistry Letters · 2009 · 55 citations · Full text

Medicinal Chemistry, Drug Target, Biochemistry +10

A small molecule mitigates hearing loss in a mouse model of Usher syndrome III

Kumar N. Alagramam, Suhasini R. Gopal, Ruishuang Geng et al. · Nature Chemical Biology · 2016 · 45 citations

Small Molecule Mitigates, Knockout Mouse, Molecular Physiology +14